Avalo Therapeutics Has Dosed The First Patient In The Phase 2 LOTUS Trial Of AVTX-009 In Hidradenitis Suppurativa, Topline Data From The Global Study In Approximately 180 Adults Is Expected In 2026
Avalo Therapeutics Has Dosed The First Patient In The Phase 2 LOTUS Trial Of AVTX-009 In Hidradenitis Suppurativa, Topline Data From The Global Study In Approximately 180 Adults Is Expected In 2026
Avalo Therapeutics已给顶ＩL-25抑制剂复合物（AVTX-009）用于HS的2期LOTUS试验第一名患者接受了剂量，来自全球研究的180名成年患者的上线数据预计将于2026年出现。
Avalo Therapeutics Has Dosed The First Patient In The Phase 2 LOTUS Trial Of AVTX-009 In Hidradenitis Suppurativa, Topline Data From The Global Study In Approximately 180 Adults Is Expected In 2026
Avalo Therapeutics已为AVTX-009在丘疹性汗腺炎的2期LOTUS试验中给第一位患者注射了剂量，全球范围内大约180名成年患者的头筹数据预计将于2026年公布。
资讯热榜
更新时间